Leading Product Revenue

May 15, 2026
Unit : Million yen

Brand name Indications April to September Annual
FY2025 FY2026
(Estimated) 		FY2024 Percentage
change 		FY2025 FY2026
(Estimated)
Viltepso 10,349 11,100 21,782 △2.7% 21,188 22,300
(Japan) Duchenne muscular dystrophy (2,386) (2,400) (4,664) 2.4% (4,775) (4,800)
(U.S.) (7,963) (8,700) (17,117) △4.1% (16,413) (17,500)
Uptravi Pulmonary arterial hypertension/
Chronic thromboembolic pulmonary hypertension 		8,448 9,200 14,971 17.5% 17,593 19,200
Erleada Prostate cancer 0 7,200 0 - 5,961 14,400
Vyxeos High-risk acute myeloid leukemia 2,941 3,100 5,139 11.7% 5,742 6,500
Gazyva CD20-positive follicular
lymphoma/
CD20-positive chronic
lymphocytic leukemia 		2,451 2,500 4,821 5.3% 5,076 5,100
Fintepla Seizures associated with
Dravet syndrome/
Seizures associated with
Lennox-Gastaut
syndrome 		1,765 3,000 2,067 92.5% 3,980 6,100
Defitelio Sinusoidal obstruction syndrome 1,252 1,300 2,364 6.3% 2,514 2,600
Cialis Erectile dysfunction 1,119 1,000 2,425 △8.4% 2,221 2,000
Deramiocel (U.S.) Duchenne muscular dystrophy cardiomyopathy 0 0 0 - 0 11,400
Profit in co-promotion 4,792 4,500 9,170 △2.2% 8,964 8,600
Revenues from the licensing of industrial property rights 24,181 27,300 45,585 8.5% 49,457 53,000
Pharmaceuticals 68,561 83,500 138,654 7.1% 148,484 176,500
Functional Food 11,086 11,500 21,577 3.3% 22,287 23,500
Revenue 79,647 95,000 160,232 6.6% 170,771 200,000

(Revenue based on the NHI drug price)

Jaypirca* Mantle cell lymphoma
Chronic lymphocytic leukemia 		1,086 - 780 236.5% 2,626 -

* Sales forecasts for Jaypirca are not disclosed.

Related Link

Nippon Shinyaku’s DNA
Sustainability
Research & Development
Annual Report

Business/Financial Information